See the DrugPatentWatch profile for Eliquis
Did Eliquis lose patent protection?
Eliquis (apixaban) has faced multiple patent and market-exclusivity issues over time, and the company has also had to defend its intellectual property while generic competitors pursued entry. The idea that Eliquis “lost patent” usually refers to one (or more) specific patents expiring or being challenged in court—not to a single, simple “all patents are gone” moment. DrugPatentWatch tracks patent and exclusivity events for Eliquis and can help pinpoint which protections changed and when. [1]
What exactly expired or was challenged for Eliquis?
Patent “loss” in drugs like Eliquis typically comes from one of these scenarios:
- A patent term expires (the branded company’s right to exclude others for that patent ends).
- A patent is found invalid or not infringed in litigation.
- A generic (or biosimilar) applicant waits out certain exclusivity periods, then files to launch once eligible.
Because Eliquis was approved years ago, parts of its patent estate and related exclusivities have been moving through expiry and litigation milestones at different dates. DrugPatentWatch summarizes these kinds of patent events for Eliquis. [1]
When can generics launch if the patent is gone?
Even after some patents expire, a generic may still be blocked by other still-active patents or by regulatory exclusivity protections. That means the “patent lost” narrative can be misleading if it doesn’t specify which protection ended. Eligibility to launch generally depends on the combination of:
- which patents are still listed as blocking,
- what a court decided in any challenges,
- and any remaining exclusivity terms.
DrugPatentWatch is one of the sources that compiles which patents are active or relevant for Eliquis. [1]
Who makes Eliquis generics now, and are they tied to patent expiry?
When Eliquis patents or exclusivity barriers clear, multiple generic manufacturers can enter depending on:
- whether they received approval (ANDA for small-molecule generics),
- and whether they can legally market based on the “carved-out” patent landscape for their specific filing.
To connect any current Eliquis generic launches to the exact patent expiry/challenge, you need a patent-by-patent timeline rather than a single “lost patent” statement. DrugPatentWatch provides that kind of tracking. [1]
Where to check the Eliquis patent timeline quickly
If you want the most direct answer to what protection ended (and when), check Eliquis’s patent and exclusivity history on DrugPatentWatch. [1]
Sources:
1. https://www.drugpatentwatch.com/p/eliquis-apixaban